Newsroom

Monarch Medical Technologies, maker of EndoTool® Glucose Management System, is pleased to announce the establishment of its Clinical Advisory Board. Comprising experts and thought leaders from diverse medical disciplines, this board will play a pivotal role in guiding our mission to revolutionize glycemic management. The formation of the Clinical Advisory Board is a testament to Monarch Medical Technologies’ commitment to staying at the forefront of innovation. By assembling a team of prominent professionals, we aim to ensure that our solutions

Semler Scientific, Inc. is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Semler Scientific’s mission is to develop, manufacture and market innovative products and services that assist its customers in evaluating and treating chronic diseases.

Monarch Medical Technologies, maker of the EndoTool® Glucose Management System, received FDA clearance for its enhanced software for the treatment of inpatient hyperglycemia using subcutaneous insulin.

Monarch Medical Technologies has earned ISO 13485:2016 certification for its quality management system from the independent certifying body, TÜV SÜD.

Mercyhealth, a multi-regional healthcare system serving northern Illinois and southern Wisconsin, is partnering with Monarch Medical Technologies to improve care for patients with diabetes or stress-induced hyperglycemia.

Monarch and Voluntis are partnering to offer a complimentary webinar, “How Technology Can Support Adoption of Best Practices for Inpatient and Outpatient Insulin Management.”

An article published by MD Magazine (now HCPLive) explores the findings of a study on the correlation between late blood glucose checks and incidence of hypoglycemia, presented by Dr. Patrick Burgess at the American Diabetes Association Scientific Sessions.

The company has obtained an additional clearance for an optional insulin-on-board (IOB) calculation to mitigate the risk of low glucose values as a result of residual rapid-acting insulin.

Monarch will be participating in the DiabetesMine D-Data ExChange on June 7, 2019 and the American Diabetes Association’s 79th Scientific Sessions on June 7-11, 2019 in San Francisco, CA.

The two studies analyze a database of nearly one million blood glucose readings from approximately 45,000 patients who were prescribed intravenous insulin dose recommendations using the EndoTool® Glucose Management System.

The complimentary webinar, “Breaking the Barriers of Inpatient Glycemic Management Quality Improvement,” features Dr. Sandy Fogel of Carilion Clinic.

Available to EndoTool clients, the portal provides the ability to research relevant topics, interact with other users, and pose questions to both the Monarch team and other client organizations.

Joining a board of diabetes experts, Dr. Vanderwel will bring expertise in pediatric endocrinology to support Monarch in the continual advancement of the EndoTool® Glucose Management System.

An article published by Drs. Pedro Salinas and Carlos Mendez in the Journal of Diabetes Science and Technology explores the efficacy of technology solutions for glycemic care in the hospital setting, with a specific focus on the critically ill patient population.

An article published by Insulin Nation explores the past, present and future of automated insulin dosing, including various tools and algorithms used within the hospital setting and new developments such as CGM and insulin pumps for the outpatient setting.